Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aegerion seeks US, European nods for lipid disorder drug

This article was originally published in Scrip

Executive Summary

Taking aim at drugs like Merck's Vytorin (ezetimibe/simvastatin) in the homozygous familial hypercholesterolemia (HoFH) marketplace, Massachusetts biotech Aegerion Pharmaceuticals is seeking approval in the US and Europe for its lead experimental medicine lomitapide as an adjunct to a low fat diet and other lipid-lowering therapies to reduce cholesterol in patients with the rare genetic lipid disorder.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts